Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary A Piazza

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|September 3, 2024
Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent TranscriptionSara Sigler, Mohammad Abdel-Halim, Reem K Fathalla, et al.
Bioorganic Chemistry|July 30, 2021
Novel thiazolidine derivatives as potent selective pro-apoptotic agentsDonia E Hafez, Eman Hafez, Islam Eddiasty, et al.
Archiv Der Pharmazie|July 30, 2019
Design and synthesis of 1,2,4-triazolo[1,5-a]pyrimidine derivatives as PDE 4B inhibitors endowed with bronchodilator activityRehab H Abd El-Aleam, Riham F George, Kevin J Lee, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 5, 2012
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activityJason D Whitt, Nan Li, Heather N Tinsley, et al.
Cancers|July 29, 2020
Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to ChemotherapyAikaterini Emmanouilidi, Ilaria Casari, Begum Gokcen Akkaya, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 9, 2022
A novel sulindac derivative protects against oxidative damage by a cyclooxygenase-independent mechanismShailaja Kesaraju Allani, Ramanjaneyulu Rayala, Oscar Rivera, et al.
Cancer Research|May 20, 2016
Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1αSangbin Lim, Hao Liu, Luciana Madeira da Silva, et al.
Frontiers in Pharmacology|December 23, 2021
Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate CancerTaraswi Mitra Ghosh, Jason White, Joshua Davis, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsDaniela De Nobrega, Logan C Eiler, Parmanand Ahirwar, et al.
Journal for Immunotherapy of Cancer|July 26, 2022
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapyNada S Aboelella, Caitlin Brandle, Ogacheko Okoko, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Anti-Cancer Agents in Medicinal Chemistry|September 3, 2024
Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent TranscriptionSara Sigler, Mohammad Abdel-Halim, Reem K Fathalla, et al.
Bioorganic Chemistry|July 30, 2021
Novel thiazolidine derivatives as potent selective pro-apoptotic agentsDonia E Hafez, Eman Hafez, Islam Eddiasty, et al.
Archiv Der Pharmazie|July 30, 2019
Design and synthesis of 1,2,4-triazolo[1,5-a]pyrimidine derivatives as PDE 4B inhibitors endowed with bronchodilator activityRehab H Abd El-Aleam, Riham F George, Kevin J Lee, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 5, 2012
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activityJason D Whitt, Nan Li, Heather N Tinsley, et al.
Cancers|July 29, 2020
Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to ChemotherapyAikaterini Emmanouilidi, Ilaria Casari, Begum Gokcen Akkaya, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 9, 2022
A novel sulindac derivative protects against oxidative damage by a cyclooxygenase-independent mechanismShailaja Kesaraju Allani, Ramanjaneyulu Rayala, Oscar Rivera, et al.
Cancer Research|May 20, 2016
Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1αSangbin Lim, Hao Liu, Luciana Madeira da Silva, et al.
Frontiers in Pharmacology|December 23, 2021
Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate CancerTaraswi Mitra Ghosh, Jason White, Joshua Davis, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsDaniela De Nobrega, Logan C Eiler, Parmanand Ahirwar, et al.
Journal for Immunotherapy of Cancer|July 26, 2022
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapyNada S Aboelella, Caitlin Brandle, Ogacheko Okoko, et al.
Pageof 12